Apotex Health Corp. launched Monday its prior disclosed initial public offering of common shares in the company and the commencement of its roadshow following the filing of an amended and restated preliminary base PREP prospectus with the securities regulatory authorities in each of the provinces and territories of Canada.
The company in a statement said the offering is expected to be between 41,666,671 and 50,000,006 common shares at a price each between $20.00 and $24.00, for gross proceeds of approximately $1 billion.
Monday's statement noted the offering consists of a treasury offering by Apotex of between 35,416,666 and 42,500,000 common shares at the offering price, for gross proceeds of approximately $850 million to Apotex, and a secondary offering by certain shareholders of the company of between 6,250,005 and 7,500,006 common shares at the offering price, for gross proceeds of approximately $150 million to the selling shareholders.
The selling shareholders are expected to grant an over-allotment option to the underwriters to purchase up to an additional 6.25 million to 7.5 million common hares at the offering price, exercisable at any time, in whole or in part, until 30 days after the closing date of the offering, to cover over-allotments, if any, and for market stabilization purposes, the statement also noted.
eadquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.